确定一种用于预测汉方（日本传统）药物桂枝茯苓丸对类风湿性关节炎患者有益效果的生物标志物。

Identification of a predictive biomarker for the beneficial effect of a Kampo (Japanese traditional) medicine keishibukuryogan in rheumatoid arthritis patients.

作者信息

Ogawa Kazuo, Kojima Tetsuko, Matsumoto Chinami, Kamegai Satoshi, Oyama Takuya, Shibagaki Yukari, Muramoto Hiroshi, Kawasaki Tetsuo, Fujinaga Hiroshi, Takahashi Kozo, Hikiami Hiroaki, Goto Hirozo, Kiga Chizuru, Koizumi Keiichi, Sakurai Hiroaki, Shimada Yutaka, Yamamoto Masahiro, Terasawa Katsutoshi, Takeda Shuichi, Saiki Ikuo

机构信息

Central Research Laboratories, Tsumura and Co., Ibaraki, Japan.

出版信息

Clin Biochem. 2007 Oct;40(15):1113-21. doi: 10.1016/j.clinbiochem.2007.06.005. Epub 2007 Jul 3.

DOI:10.1016/j.clinbiochem.2007.06.005

PMID:17673196

Abstract

OBJECTIVES

Kampo (Japanese traditional herbal) medicines are now ethically used in Japan as pharmaceutical grade prescription drugs. However, there are distinct groups of responders and non-responders to Kampo medicines. We searched for biomarker candidates to discriminate responders from non-responders to keishibukuryogan (KBG); one of the most frequently used Kampo medicines.

DESIGN AND METHODS

A combination of SELDI technology and a decision tree analysis with proprietary developed bioinformatics tools was applied to 41 (32 for tree construction and 9 for validation test) plasma samples obtained from rheumatoid arthritis (RA) patients. A candidate biomarker protein was identified using LC-MS/MS.

RESULTS

The constructed tree with measurable reliability contained only a single peak which was identified as haptoglobin alpha 1 chain (Hpalpha1).

CONCLUSION

Hpalpha1 is a biomarker candidate for discriminating responders from non-responders to KBG treatment for RA. The present results may open the way to the establishment of "evidence-based" complementary and alternative medicine.

摘要